ERBB2 and breast cancer: To assess the efficacy of our iGenSig-Rx method in modeling clinical trial datasets, we leveraged multiple genomic datasets from breast cancer patients undergoing HER2 targeted therapy in CALGB 40601, ACOSOG Z1041, NOAH, and NSABP B-41 trials.